Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan

Journal of the Formosan Medical Association

Volumn 113, Issue 10, 2014, Pages 727-733

  Lin, Jung An ^a   Chen, Yeu Chin ^a   Cheng, Shin Nan ^a   Chen, Peng Jen ^a   Chu, Heng Cheng ^a   Hsieh, Tsai Yuan ^a   Shih, Yu Lueng ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Hemophilia; Hepatitis C; Pegylated interferon; Ribavirin; Viral response

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CREATININE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SERUM ALBUMIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HUMAN TISSUE; INSOMNIA; LIVER CELL CARCINOMA; LUNG TUBERCULOSIS; MAJOR DEPRESSION; MALE; MIDDLE AGED; MYALGIA; NEUTROPENIA; PROSPECTIVE STUDY; PRURITUS; SEPSIS; SUSTAINED VIROLOGICAL RESPONSE; TAIWAN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C, CHRONIC; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; GENOTYPE; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TAIWAN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84922672673     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.10.010     Document Type: Article

References (32)

1. Yee T., Griffioen A., Sabin C.A., Dusheiko G., Lee C. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000, 47:845-851.
2. Rumi M.G., Colombo M., Gringeri A., Mannucci P.M. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990, 112:379-380.
3. Chen D.S., Kuo G.C., Sung J.L., Lai M.Y., Sheu J.C., Chen P.J., et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 1990, 162:817-822.
4. Franchini M. Hepatitis C in haemophiliacs. Thromb Haemost 2004, 92:1259-1268.
5. Lee C., Dusheiko G. The natural history and antiviral treatment of hepatitis C in haemophilia. Haemophilia 2002, 8:322-329.
6. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673-1680.
7. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
8. Zeuzem S., Feinman S.V., Rasenack J., Heathcote E.J., Lai M.Y., Gane E., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666-1672.
9. Franchini M., Mengoli C., Veneri D., Mazzi R., Lippi G., Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother 2008, 61:1191-1200.
10. Lee S.D., Chan C.Y., Wang Y.J., Wu J.C., Lai K.H., Tsai Y.T., et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991, 13:830-833.
11. Seeff L.B., Hollinger F.B., Alter H.J., Wright E.C., Cain C.M., Buskell Z.J., et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33:455-463.
12. Zhang M., Rosenberg P.S., Brown D.L., Preiss L., Konkle B.A., Eyster M.E., et al. Correlates of spontaneous clearance of hepatitis C virus among people with hemophilia. Blood 2006, 107:892-897.
13. Liu C.J., Chuang W.L., Lee C.M., Yu M.L., Lu S.N., Wu S.S., et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504. e3.
14. Liu C.H., Liu C.J., Lin C.L., Liang C.C., Hsu S.J., Yang S.S., et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
15. Yu M.L., Dai C.Y., Huang J.F., Chiu C.F., Yang Y.H., Hou N.J., et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008, 47:1884-1893.
16. Yu M.L., Dai C.Y., Lin Z.Y., Lee L.P., Hou N.J., Hsieh M.Y., et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006, 26:73-81.
17. Chuang W.L., Yu M.L., Dai C.Y., Chang W.Y. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006, 49:99-106.
18. Yu M.L., Dai C.Y., Huang J.F., Hou N.J., Lee L.P., Hsieh M.Y., et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007, 56:553-559.
19. Yu M.L., Chuang W.L. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009, 24:336-345.
20. Huang C.F., Huang J.F., Yang J.F., Hsieh M.Y., Lin Z.Y., Chen S.C., et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol 2012, 56:34-40.
21. Liu C.H., Liang C.C., Liu C.J., Tseng T.C., Lin C.L., Yang S.S., et al. Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy. Antivir Ther 2012, 17:477-484.
22. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
23. Witkos M., Yi Q.L., Heathcote J., Kapral M.K., Krahn M.D. Predictors of antiviral therapy in a post-transfusion cohort of hepatitis C patients. Can J Gastroenterol 2006, 20:107-111.
24. Posthouwer D., Plug I., van der Bom J.G., Fischer K., Rosendaal F.R., Mauser-Bunschoten E.P. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005, 11:270-275.
25. Kevans D., Farrell G., Hopkins S., Mahmud N., White B., Norris S., et al. Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Haemophilia 2007, 13:593-598.
26. Pockros P.J., Shiffman M.L., Schiff E.R., Sulkowski M.S., Younossi Z., Dieterich D.T., et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004, 40:1450-1458.
27. Koirala J., Gandotra S.D., Rao S., Sangwan G., Mushtaq A., Htwe T.H., et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 2007, 14:782-787.
28. Collantes R.S., Younossi Z.M. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005, 39:S9-S13.
29. Shiffman M.L., Salvatore J., Hubbard S., Price A., Sterling R.K., Stravitz R.T., et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007, 46:371-379.
30. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004, 126:1302-1311.
31. Alavian S.M., Tabatabaei S.V., Keshvari M., Behnava B., Miri S.M., Elizee P.K., et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 2010, 30:1173-1180.
32. Yang J.F., Kao Y.H., Dai C.Y., Huang J.F., Hsieh M.Y., Lin Z.Y., et al. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Hepatol Int 2010, 4:732-740.